Mounjaro vs Zepbound 2026: Same Medication, Different Approval (Cost Comparison)
Mounjaro and Zepbound contain the same drug (tirzepatide) but are FDA-approved for different conditions. Cost, insurance coverage, savings cards, and how the compounded pathway differs in 2026.
Quick Verdict: Same Drug, Different Labels
Mounjaro and Zepbound are the same medication (tirzepatide, made by Eli Lilly). The only difference is FDA approval: Mounjaro for type 2 diabetes, Zepbound for weight loss. Cash-pay cost is similar (~$1,000-$1,200/mo).
A separate route exists for cash-pay patients: compounded tirzepatide at $125/month flat, prepared per individual prescription under the FDA-recognized 503A/503B compounding pathway and not FDA-approved as a drug product.
About this comparison
Information based on publicly available FDA labels, Eli Lilly product information, and cash-pay pricing as of May 2026. Both Mounjaro and Zepbound are legitimate FDA-approved medications. Compounded tirzepatide is dispensed under FDA 503A or 503B pathways from licensed compounding pharmacies. This article is informational and not medical advice.
More on Tirzepatide Brand Names & Cost
Compounded Tirzepatide vs Brand Name
Regulatory and safety differences vs Mounjaro/Zepbound.
Compounded Tirzepatide vs Zepbound 2026
How the two pathways differ in oversight and access.
Cheapest Tirzepatide Online
Lowest-cost path to tirzepatide treatment.
Best Telehealth GLP-1 Providers Ranked 2026
National ranking of compounded GLP-1 providers.
The Core Fact: Same Active Ingredient
Both Mounjaro and Zepbound contain tirzepatide as the active ingredient. Tirzepatide is a dual GIP/GLP-1 receptor agonist developed by Eli Lilly. The molecule, formulation, doses (2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg), and pen delivery system are identical across both products.
If you're prescribed Mounjaro at 10mg weekly, it works exactly the same as Zepbound at 10mg weekly. The difference isn't pharmacological, it's regulatory and commercial.
Side-by-Side Comparison Table
| Factor | Mounjaro | Zepbound | Compounded Tirzepatide (Trimi) |
|---|---|---|---|
| Active ingredient | Tirzepatide | Tirzepatide | Tirzepatide |
| Manufacturer | Eli Lilly | Eli Lilly | Licensed 503A/503B compounding pharmacy |
| FDA approval | Type 2 diabetes (May 2022) | Chronic weight management (Nov 2023) | 503A/503B compounding pathway |
| Cash price (monthly) | ~$1,000-$1,200/mo | ~$1,000-$1,200/mo | Flat cash-pay rate (not insurance-billed) |
| Annual cash cost | ~$12,000-$14,400/yr | ~$12,000-$14,400/yr | 12 equal monthly payments |
| Insurance coverage probability | High (for diabetes diagnosis) | Variable (depends on employer plan) | N/A, cash-pay model bypasses insurance |
| Doses available | 2.5/5/7.5/10/12.5/15mg | 2.5/5/7.5/10/12.5/15mg | Same range, dosed by clinician |
Why Two Brand Names?
Pharmaceutical companies typically launch a separate brand for each FDA-approved indication. This isn't unique to tirzepatide, semaglutide has the same dual-brand pattern (Ozempic for diabetes, Wegovy for weight loss).
Reasons for the dual-brand approach:
- Regulatory clarity: Each FDA approval is for a specific condition, with its own clinical trial data. Distinct labels make insurance billing cleaner.
- Commercial positioning: Marketing diabetes treatment vs weight loss to different audiences. Each brand has its own messaging, packaging, and patient education.
- Insurance dynamics: Diabetes drugs typically have higher insurance coverage rates. Selling the diabetes version separately preserves that coverage path.
- Pricing leverage: Eli Lilly can adjust pricing for each brand independently based on the specific market dynamics (formulary negotiations, employer benefit programs, etc.).
Cash-Pay Reality: Why Both Cost ~$1,000+/Month
Without insurance, both Mounjaro and Zepbound cost approximately $1,000-$1,200/month at retail pharmacies in 2026. Eli Lilly offers savings cards that can reduce out-of-pocket cost in some scenarios:
- Mounjaro Savings Card: May reduce cost to $25/month for eligible commercially insured patients (with diabetes diagnosis). Strict eligibility, most cash-pay patients don't qualify.
- Zepbound Savings Card: Available for commercially insured patients without coverage; ~$650/month for eligible self-pay patients in some scenarios. Eligibility caps and program changes apply.
- LillyDirect: Eli Lilly's direct-to-patient program offers Zepbound at ~$500-$549/month for self-pay patients. Not the same as standard pharmacy pricing.
For most patients without insurance who don't qualify for the savings cards, Mounjaro and Zepbound are economically prohibitive at $12,000-$14,400/year.
The Compounded Tirzepatide Alternative
During FDA's 2023-2024 declaration of tirzepatide as in shortage, licensed compounding pharmacies were authorized to produce tirzepatide for patient prescriptions. Many telehealth providers continue to offer compounded tirzepatide under the FDA 503A and 503B pathways, on flat cash-pay terms rather than through insurance.
Trimi's compounded tirzepatide is $125/month, priced below most national telehealth competitors:
- Prepared per individual prescription; not FDA-approved as a drug
- Sourced from licensed 503A or 503B compounding pharmacies
- $125/month flat, no membership fee, no shipping fee
- 10-15 minute online intake; provider review in 24-48 hours; medication ships free overnight once compounded
- Billed the same amount every month, with no claim, deductible, or prior authorization
Important: compounded tirzepatide is not an FDA-approved drug product and has not been reviewed by the FDA for safety, effectiveness, or manufacturing quality. Whether it is appropriate for you is a clinical decision for a licensed provider.
When to Choose Mounjaro
Mounjaro is the right pick if:
- You have type 2 diabetes (Mounjaro is FDA-approved for this, insurance coverage is more likely)
- Your insurance covers Mounjaro and the copay is reasonable
- You qualify for the Mounjaro Savings Card and the discounted price beats compounded options
- You specifically want the Eli Lilly-manufactured brand-name product
When to Choose Zepbound
Zepbound is the right pick if:
- You're using tirzepatide specifically for weight loss (not diabetes)
- Your employer's insurance plan includes weight loss medication coverage
- You qualify for the Zepbound Savings Card and the price is comparable to alternatives
- LillyDirect's $500-$549/month self-pay option fits your budget
When to Choose Compounded Tirzepatide
Compounded tirzepatide is the right pick if:
- You're paying cash and don't have insurance coverage for either brand
- A predictable, flat monthly amount matters more to you than insurance billing
- You don't qualify for Eli Lilly's savings cards or LillyDirect
- You prefer telehealth convenience (no in-person pharmacy pickup required)
- You're comfortable with the FDA 503A/503B compounding pathway as a legitimate medical option
Frequently Asked Questions
Are Mounjaro and Zepbound the same medication?
Yes, Mounjaro and Zepbound contain the same active ingredient (tirzepatide) at the same doses (2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg). Both are made by Eli Lilly. The only difference is FDA approval pathway: Mounjaro is approved for type 2 diabetes; Zepbound is approved for chronic weight management.
Why does Eli Lilly sell the same drug under two names?
Regulatory and commercial. The FDA approves drugs for specific indications, and pharmaceutical companies typically launch a brand name for each indication. Mounjaro launched first (May 2022, for diabetes); Zepbound launched second (November 2023, for weight loss). Same molecule, two FDA labels, two prescription paths.
Which costs more, Mounjaro or Zepbound?
Cash price is similar, both run approximately $1,000-$1,200/month without insurance in 2026. With insurance, Mounjaro is more often covered (because diabetes coverage is more standard than weight loss coverage). Zepbound coverage is less common but expanding as employers add anti-obesity benefits.
Can I switch from Mounjaro to Zepbound?
Yes, your provider can switch your prescription. Same molecule, same dose, same effect, only the label changes. Some patients switch because their insurance covers one but not the other. Your weight loss results, side effects, and titration schedule are identical.
What tirzepatide options exist in 2026?
Mounjaro and Zepbound are the two FDA-approved brand-name products, both from Eli Lilly. Compounded tirzepatide is a separate route: Trimi offers it at $125/month flat, cash-pay. The two sit in different regulatory categories: FDA-approved brand versus a compounded preparation made under the 503A/503B pathway, which is not FDA-approved as a drug.
How does compounded tirzepatide differ from Mounjaro and Zepbound?
Mounjaro and Zepbound are FDA-approved products backed by pharmacokinetic studies and uniform manufacturing. Compounded tirzepatide is prepared per individual prescription by a licensed 503A/503B pharmacy and is not FDA-approved as a drug, so quality controls at the pharmacy matter. How you access and pay for each also differs: brand runs through retail pharmacy and insurance, compounded through telehealth on a flat cash-pay basis. Ask your prescribing clinician which route fits your situation.
Will insurance cover Mounjaro for weight loss?
Generally no. Mounjaro is FDA-approved for type 2 diabetes, so insurance typically only covers it for that diagnosis. If you have diabetes AND want weight loss benefit, your doctor may prescribe Mounjaro and insurance may cover it. For weight loss alone (no diabetes), Zepbound is the FDA-approved option, and insurance coverage varies by employer plan.
Disclaimer: Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. This article is informational and not medical advice. Both brand-name and compounded tirzepatide are legitimate medications under different regulatory pathways. Pricing is current as of May 2026 and subject to change. Always consult a licensed clinician about whether tirzepatide is appropriate for your individual health situation.